Alaunos Therapeutics, INC. (TCRT) — 10-Q Filings

10-Q Filings (6)

• Alaunos Narrows 9-Month Loss, Boosts Cash Amid Strategic Shift — Nov 14, 2025 Risk: high
  Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $1.159 million for the three months ended September 30, 2025, a slight increase from the $1.127 million
• Alaunos Narrows Losses, Boosts Cash Amid Nasdaq Delisting Threat — Aug 14, 2025 Risk: high
  Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $1.051 million for the three months ended June 30, 2025, a slight improvement from the $1.129 million n
• Alaunos Therapeutics Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key dates and ag
• Alaunos Therapeutics Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Alaunos Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and operational activities
• Alaunos Therapeutics Files 10-Q, Details R&D and G&A Expenses — Aug 14, 2024 Risk: medium
  Alaunos Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses for the six months ended J
• Alaunos Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: medium
  Alaunos Therapeutics, Inc. (TCRT) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Alaunos Therapeutics, Inc. (TCRT) filed a 10-Q for the quarter e

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX